| Literature DB >> 36181089 |
Sera Cetingok1, Oznur Seker2, Halil Cetingok3.
Abstract
The study aims to determine whether there is a relationship between fibromyalgia (FM) disease and depression, anxiety, anxiety sensitivity, fear-avoidance beliefs, and quality of life in female patients with a diagnosis of fibromyalgia. 37 female patients followed up with FM diagnosis in pain medicine clinic and a control group consisting of 37 healthy women were included in the study. Sociodemographic and Clinical Characteristics Data Form, Quality of Life Form, fear-avoidance beliefs questionnaire, Anxiety Sensitivity Index-3, Beck Anxiety Inventory, Beck Depression Inventory, and Visual Analogue Scale was applied to the participants. When the patients in the FM group were compared to the control group; Statistically lower scores in all Quality of Life Form subscales except emotional role difficulty and social functionality scores; statistically higher scores in both physical and work activity subscales in fear-avoidance beliefs questionnaire; statistically higher scores in cognitive symptoms subscale in Anxiety Sensitivity Index-3, Beck Anxiety Inventory, Beck Depression Inventory, and Visual Analogue Scale scores were found. In FM patients, it has been determined that anxiety, depression and perceived pain severity reduce social functionality and quality of life in areas such as mental health, physical function, and emotional role difficulties. It was determined that the functionality and quality of life of patients diagnosed with FM decreased in daily life. An important contribution of the study to the literature is that it shows that the behavior of avoiding activity due to pain-induced fear exacerbates the pain and even contributes to its chronicity. These results, which show the effects of anxiety, depression, anxiety sensitivity, and fear-avoidance behavior on the prognosis of the disease in FM patients, indicate that psychiatric evaluation and treatment in FM patients is an important factor that determines the functionality and quality of life.Entities:
Mesh:
Year: 2022 PMID: 36181089 PMCID: PMC9524976 DOI: 10.1097/MD.0000000000030868
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Comparison of sociodemographic characteristics.
| N = 74 | Control group (n = 37) | Patient group (n = 37) |
|
| |
|---|---|---|---|---|---|
| Mean ± SD (median) | Mean ± SD (median) | ||||
| Age | 45.08 ± 10.53 (43) | 45.97 ± 9.95 (46) | −0.374 | .709 | |
|
|
| ||||
| Sex | Woman | 37 (100) | 37 (100) | 1.000 | |
| Man | – | – | |||
| Education status | Primary | 14 (37.8) | 19 (51.4) | 1.502 | .682 |
| Middle | 9 (24.3) | 8 (21.6) | |||
| High | 8 (21.6) | 6 (16.2) | |||
| University | 6 (16.2) | 4 (10.8) | |||
| Habit | None | 27 (73.0) | 31 (83.8) | 1.806 | .398 |
| Smoking | 9 (24.3) | 6 (16.2) | |||
| Alcohol | 1 (2.7) | 0 (0.0) | |||
SD = standard deviation.
Student t test,
Fisher exact chi-square,
*P < .05 (mean ± SD).
Comparison of 36-item short form survey results.
| N = 74 | Mean ± SD (median) |
| ||
|---|---|---|---|---|
| Control group (n = 37) | Patient group (n = 37) | |||
| Physical functioning | 75.54 ± 24.26 (85) | 47.56 ± 21.59 (50) | 267.00 | <.001 |
| Role physical | 65.54 ± 39.68 (75) | 13.51 ± 31.50 (0) | 225.00 | <.001 |
| Role emotional | 56.75 ± 35.88 (67) | 33.33 ± 44.44 (0) | 457.50 | .010 |
| Energy/fatigue | 50.00 ± 20.44 (45) | 24.86 ± 23.87 (15) | 312.50 | <.001 |
| Emotional well-being | 66.92 ± 15.39 (64) | 46.48 ± 21.55 (48) | 323.00 | <.001 |
| Social functioning | 68.24 ± 19.84 (75) | 50.00 ± 30.47 (50) | 443.00 | .008 |
| Bodily pain | 71.95 ± 23.99 (78) | 32.43 ± 25.00 (30) | 180.50 | <.001 |
| General health perceptions | 59.05 ± 17.43 (60) | 31.75 ± 20.18 (35) | 6.226 | <.001 |
SD = standard deviation.
Mann–Whitney U test,
Student t test
P < .006 [P value with Bonferroni correction (.05/number of comparisons; .05/8)] (mean ± SD).
Comparison of fear avoidance belief questionnaire results.
| N = 74 | Mean ± SD (median) |
|
| |
|---|---|---|---|---|
| Control group (n = 37) | Patient group (n = 37) | |||
| Physical activity | 7.92 ± 9.58 (4) | 21.26 ± 8.80 (22) | 213.00 | <.001 |
| Work activity | 3.64 ± 6.16 (0) | 24.73 ± 17.95 (27) | 221.50 | <.001 |
SD = standard deviation.
Mann–Whitney U test
P < .025 [P value with Bonferroni correction (.05/number of comparisons; .05/2)] (mean ± SD).
Comparison of Anxiety Sensitivity Index-3 results.
| N = 74 | Mean ± SD (median) |
|
| |
|---|---|---|---|---|
| Control group (n = 37) | Patient group (n = 37) | |||
| Physical concerns | 17.37 ± 11.05 (17) | 17.78 ± 8.53 (19) | 615.50 | .455 |
| Social concerns | 15.18 ± 6.31 (13) | 20.48 ± 8.78 (19) | 429.50 | .006 |
| Cognitive concerns | 10.27 ± 4.48 (9) | 13.24 ± 6.20 (12) | 496.00 | .041 |
SD = standard deviation.
Mann–Whitney U test,
P < .016 [P value with Bonferroni correction (.05/number of comparisons .05/3)] (mean ± SD).
Comparison of BAI, BDI, and VAS results.
| N = 74 | Mean ± SD (median) |
|
| |
|---|---|---|---|---|
| Control group (n = 37) | Patient group (n = 37) | |||
| BAI | 11.70 ± 8.91 (10) | 24.56 ± 14.70 (20) | 296.50 | <.001 |
| BDI | 9.78 ± 9.38 (8) | 21.13 ± 10.55 (19) | 240.00 | <.001 |
| VAS | 2.54 ± 2.57 (2) | 7.37 ± 1.87 (7) | 111.00 | <.001 |
BAI = Beck Anxiety Inventory, BDI = Beck Depression Inventory, SD = standard deviation, VAS = Visual Analogue Scale.
Mann–Whitney U test
P < .01 (mean ± SD).
The relationship between FABQ and ASI-3, BAI, BDI, VAS in fibromyalgia patients.
| FABQ physical | FABQ work | ||
|---|---|---|---|
| ASI-3 physical concerns | r | 0.243 | 0.296 |
| p | 0.147 | 0.09 | |
| ASI-3 cognitive concerns | r | 0.236 | −0.033 |
| p | 0.16 | 0.853 | |
| ASI-3 social concerns | r | 0.229 | 0.127 |
| p | 0.173 | 0.473 | |
| BAI | r | 0.006 | 0.061 |
| p | 0.97 | 0.731 | |
| BDI | r | 0.201 | 0.152 |
| p | 0.234 | 0.39 | |
| VAS | r | 0.204 | 0.430 |
| p | 0.226 | 0.011 | |
ASI-3 = Anxiety Sensitivity Index-3, BAI = Beck Anxiety Inventory, BDI = Beck Depression Inventory, FABQ = fear avoidance belief questionnaire, r = correlation coefficient, VAS = Visual Analogue Scale.
Spearman’s rho correlation,
P < .05.
The relationship of ASI-3 with BAI, BDI, VAS in fibromyalgia patients.
| ASI-3 physical concerns | ASI-3 cognitive concerns | ASI-3 social concerns | ||
|---|---|---|---|---|
| BAI | r | 0.365 | 0.424 | 0.345 |
| p | 0.026 | 0.009 | 0.036 | |
| BDI | r | 0.463 | 0.573 | 0.531 |
| p | 0.004 | <0.001 | 0.001 | |
| VAS | r | 0.261 | 0.114 | 0.036 |
| p | 0.118 | 0.503 | 0.834 | |
ASI-3 = Anxiety Sensitivity Index-3, BAI = Beck Anxiety Inventory, BDI = Beck Depression Inventory, r = correlation coefficient, VAS = Visual Analogue Scale.
Spearman’s rho correlation,
P < .05,
P < .01.
The relationship of ASI-3 with BAI, BDI, VAS in control group.
| ASI-3 physical concerns | ASI-3 cognitive concerns | ASI-3 social concerns | ||
|---|---|---|---|---|
| BAI | r | −0.008 | 0.400 | 0.306 |
| p | 0.964 | 0.014 | 0.066 | |
| BDI | r | 0.305 | 0.748 | 0.490 |
| p | 0.066 | <0.001 | 0.002 | |
| VAS | r | 0.495 | 0.465 | 0.472 |
| p | 0.002 | 0.004 | 0.003 | |
ASI-3 = Anxiety Sensitivity Index-3, BAI = Beck Anxiety Inventory, BDI = Beck Depression Inventory, r = correlation coefficient, VAS = Visual Analogue Scale.
Spearman’s rho correlation,
P < .05,
P < .01